2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.106 (Poster) Validation of Immunotherapy Response Score (IRS) for predicting pembrolizumab monotherapy benefit in first line (1L) non-small cell lung cancer (NSCLC)

PP01.106 (Poster) Validation of Immunotherapy Response Score (IRS) for predicting pembrolizumab monotherapy benefit in first line (1L) non-small cell lung cancer (NSCLC)

Back to course

Pdf Summary

Summary Not Available

Asset Subtitle

Brandi Oakley